What is Interius BioTherapeutics?
Founded in 2021 and based in Philadelphia, PA, Interius BioTherapeutics is an early-stage biotechnology firm dedicated to advancing cell and gene therapy. The company's core innovation lies in its next-generation delivery technology, which is built upon foundational inventions from Dr. Saar Gill's laboratory at the University of Pennsylvania. This proprietary technology aims to expand the therapeutic potential of existing and future gene therapies, positioning Interius BioTherapeutics as a key player in the rapidly evolving gene therapy landscape.
How much funding has Interius BioTherapeutics raised?
Interius BioTherapeutics has raised a total of $76M across 1 funding round:
Series A
$76M
Series A (2021): $76M with participation from Bain Capital, Fairmount Funds Management, and Cormorant Asset Management
Key Investors in Interius BioTherapeutics
Bain Capital
Bain Capital is a global investment firm with a broad platform that includes Growth & Venture capital, specializing in backing innovative companies. Their involvement suggests a focus on scaling promising technologies within the life sciences sector.
Fairmount Funds Management
Fairmount Funds Management is a Philadelphia-based investment firm with a specific focus on innovative therapies from biotechnology and life science companies, aligning perfectly with Interius BioTherapeutics' mission.
Cormorant Asset Management
Cormorant Asset Management is a life sciences investment firm that provides financial resources to promising companies in biotech, indicating a strategic interest in Interius BioTherapeutics' advanced gene therapy delivery technology.
What's next for Interius BioTherapeutics?
The substantial enterprise-level funding, particularly the recent strategic investment, signals a pivotal growth phase for Interius BioTherapeutics. This capital infusion is expected to accelerate the company's research and development efforts, potentially enabling the progression of its delivery technology through preclinical and clinical trials. The strategic nature of the recent financing suggests strong alignment with investors who are keen on the long-term potential of advanced gene therapy platforms. Interius BioTherapeutics is poised to leverage this backing to solidify its technological lead and explore strategic partnerships within the biotechnology sector, aiming to translate its innovative platform into impactful patient treatments.
See full Interius BioTherapeutics company page
